This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Klinefelter's syndrome

Authoring team

Klinefelter’s syndrome (KS) was first described by Harry Klinefelter in 1942 as an endocrine disorder of unknown etiology. In 1959, Jacobs et al recognized KS as a chromosomal disorder in which the patients had an extra X chromosome to a normal male karyotype, 46 XY (1).

  • the most common karyotype is 47 XXY which is considered to be the classic form of the disease (1)
  • also it is not uncommon to find patients with
    • sex chromosomal aneuploidies e.g. - 48,XXYY; 48,XXXY and 49,XXXXY. These men usually have similar but often more severe phenotypes than those with the XXY karyotype (3)
    • mosaicism, a mixture of both normal and 47 XXY cells or mixtures of 47 XXY and other karyotypes (2). A milder phenotype is usually seen in these patients (3)
  • phenotype of KS is relatively mild when compared to that of other autosomal trisomies (e.g., Down syndrome) (2) since the additional X chromosome is predominantly inactivated (but the entire X chromosome is not inactivated.)
  • increase in phenotypic severity is seen when the number of X chromosomes increases (3)

This is the most common cause of male hypogonadism. Majority of patients are undiagnosed due to non specific clinical findings while in some cases, diagnosis is made post mortem (4).

Increased maternal age is linked with an increased risk of having a child with KS (2). Affected individuals have a normal life span.

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.